Selection and immune recognition of HIV-1 MPER mimotopes

scientific article published on 19 September 2020

Selection and immune recognition of HIV-1 MPER mimotopes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VIROL.2020.06.016
P698PubMed publication ID32980676

P2093author name stringLindsay Wieczorek
Venigalla Rao
Mangala Rao
Victoria Polonis
Jesse Schoen
Kristina Peachman
Nicholas Steers
P2860cites workBroad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external regionQ37410792
Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.Q37547462
A new paradigm in molecular recognition? Specific antibody binding to membrane-inserted HIV-1 epitopes.Q37876373
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.Q38986943
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasmaQ40311562
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.Q40429324
Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.Q40503064
Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.Q41925820
Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopesQ43612537
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.Q45948731
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.Q51100729
Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab FragmentQ58072233
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsQ24635002
HIV: cell binding and entryQ27008983
Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41Q27312171
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesQ27485578
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membraneQ27649531
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesQ27665884
Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Q27680125
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41Q28236154
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Q31016954
An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10Q33272711
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individualsQ34047445
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesQ34324992
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMCQ34357068
The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopesQ34610233
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionQ35076717
Structure and immune recognition of trimeric pre-fusion HIV-1 Env.Q35142291
Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.Q35191547
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and PotencyQ35641369
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infectionQ35857268
The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External RegionQ35860914
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchQ35861256
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortQ35894094
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.Q36228646
Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization FingerprintingQ36239578
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.Q36974754
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individualsQ37033400
Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion stateQ37250899
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donorsQ37333772
P1104number of pages10
P304page(s)99-108
P577publication date2020-09-19
P1433published inVirologyQ7934867
P1476titleSelection and immune recognition of HIV-1 MPER mimotopes
P478volume550

Search more.